Prognostic Factors for Tumor Recurrence after a 12-Year, Single-Center Experience of Liver Transplantations in Patients with Hepatocellular Carcinoma

Author:

Cescon Matteo1,Ravaioli Matteo1,Grazi Gian Luca1,Ercolani Giorgio1,Cucchetti Alessandro1,Bertuzzo Valentina1,Vetrone Gaetano1,Del Gaudio Massimo1,Vivarelli Marco1,D'Errico-Grigioni Antonietta2,Dazzi Alessandro1,Di Gioia Paolo1,Lauro Augusto1,Pinna Antonio Daniele1

Affiliation:

1. General Surgery and Transplant Unit, Department of General Surgery and Organ Transplantation, University of Bologna, 40138 Bologna, Italy

2. Pathology Division, Department of Oncology and Hematology, The “Felice Addarii” Institute, University of Bologna, 40138 Bologna, Italy

Abstract

Background. Factors affecting outcomes after orthotopic liver transplantation (OLT) for hepatocellular carcinoma (HCC) have been extensively studied, but some of them have only recently been discovered or reassessed.Methods. We analyzed classical and more recently emerging variables with a hypothetical impact on recurrence-free survival (RFS) in a single-center series of 283 patients transplanted for HCC between 1997 and 2009.Results. Five-year patient survival and RFS were 75% and 86%, respectively. Thirty-four (12%) patients had HCC recurrence. Elevated preoperative alpha-fetoprotein (AFP) levels, preoperative treatments of HCC, unfulfilled Milan and up-to-seven criteria at final histology, poor tumor differentiation, and tumor microvascular invasion negatively affected RFS by univariate analysis. Milan and up-to-seven criteria applied preoperatively, and the use of m-TOR inhibitors did not reach statistical significance. Cox's proportional hazard model showed that only elevated AFP levels (Odds ; 95% –5.80; ), preoperative tumor treatments (Odds ; 95% –16.42; ), and microvascular invasion (Odds ; 95% –12.41; ) were predictors of lower RFS.Conclusions. Biological aggressiveness and preoperative tumor treatment, rather than traditional and expanded dimensional criteria, conditioned the outcomes in patients transplanted for HCC.

Publisher

Hindawi Limited

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3